Check for updates

Acknowledgments: The PedNet Study Group was supported by unrestricted research grants from Baxter Healthcare Cooperation (Deerfield, IL), Bayer Healthcare, Novo Nordisk, Sobi, and Biogen.

Contribution: H.M.v.d.B. and R.L. designed the research, analyzed and interpreted the data, and wrote the manuscript.

Conflict-of-interest disclosure: H.M.v.d.B. received unrestricted research support from Novo Nordisk, Wyeth, Baxter, and Bayer. R.L. received research grants, speaker fees, and consultation fees from Bayer, Baxter, Novo Nordisk, and Octapharma.

A complete list of the members of the PedNet Study Group appears in the online data supplement.

Correspondence: H. M. van den Berg, Julius Centre for Health Sciences and Primary Care, PO Box 85500, 3508 GA Utrecht, The Netherlands; e-mail: h.m.vandeberg@umcutrecht.nl.

References

- Gouw SC, van der Bom JG, Ljung R, et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231-239.
- Calvez T, Chambost H, Claeyssens-Donadel S, et al; FranceCoag Network. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. *Blood.* 2014;124(23):3398-3408.
- Collins PW, Palmer BP, Chalmers EA, et al; UK Haemophilia Centre Doctors' Organization. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. *Blood.* 2014;124(23):3389-3397.
- Berntorp E, Iorio A. Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. *Blood.* 2015;125(24):3816-3817.

DOI 10.1182/blood-2015-08-663583

© 2015 by The American Society of Hematology

To the editor:

Is there more than one way to unpack a Weibel-Palade body?

Endothelial cells respond to vascular damage by secreting concatemers of the adhesive glycoprotein von Willebrand factor (VWF) to capture blood platelets and promote hemostasis. VWF is contained in large rod-shaped secretory granules called Weibel-Palade bodies (WPBs), and how VWF is stored in and released from these organelles is of considerable interest.¹ Recently, a novel mechanism was described for VWF release in which an actomyosin ring forms around the WPB several seconds after its fusion with the plasma membrane to squeeze VWF from the WPB.² This new mechanism was described in experiments using the potent secretagogue phorbol 12-myristate 13-acetate (PMA), and has received considerable attention.³⁻⁵ However, the mechanism of action of PMA differs in several key respects from that of physiological secretagogues, such as histamine, that elevate intracellular free calcium ion concentrations ([Ca²⁺]_i). PMA action is characterized by a slow onset (tens of seconds to minutes) but a protracted (hours) period of WPB fusion that occurs without an increase in [Ca²⁺]_i. VWF is released slowly from the WPB after fusion with the plasma membrane (tens of seconds), and secretion is prevented by inhibition of protein kinase C,⁶ myosin IIB (MyoIIB),² or actin disruption or stabilization.⁷ In contrast, histamine (or ionomycin) triggers a rapid (<1 second) but transient (10-30 seconds) burst in WPB exocytosis.⁸ Ca²⁺-mediated VWF secretion is not blocked by protein kinase C inhibition⁶ or actin disruption,⁹ and early optical studies indicated that the initial expulsion of VWF occurs on a subsecond time scale (see Erent et al⁸ and references therein). On the basis of these observations we asked whether the actomyosin process represents a general mechanism for VWF release from WPBs. Our new data suggest not.

First, live-cell imaging of fluorescent VWF–enhanced green fluorescent protein (VWF-EGFP) or VWF-propeptide-EGFP (VWFpp-EGFP) expulsion from individual WPBs shows this process to be fast (Figure 1Ai-ii). Second, dual-color imaging of endothelial cells coexpressing VWFpp-EGFP or VWFpp-mCherry and either TagRFPactin (Figure 1Bi-ii) or MyoIIB-GFP (Figure 1Ci-ii) revealed no evidence of redistribution or accumulation of actin or MyoIIB to WPBs undergoing exocytosis. Third, MyoIIB inhibition by blebbistatin did not prevent histamine-evoked VWF secretion (Figure 1D), and we have reconfirmed that actin disruption or stabilization fails to prevent Ca²⁺-mediated VWF secretion. Because myosin II may subtly regulate the opening of secretory granule fusion pores (reviewed in Porat-Shliom et al³), we also performed amperometry studies but found no major effects of MyoIIB inhibition on WPB fusion pore formation or expansion (Figure 1E). Together, the data suggest that expulsion of VWF from WPBs during Ca^{2+} -driven WPB exocytosis does not involve actomyosin.

What other mechanism might account for fast actomyosinindependent VWF expulsion during Ca²⁺-mediated exocytosis? Studies of mucins, large multimeric glycoproteins closely related to VWF, suggest that the subsecond expulsion of these charged polymers from mucin granules is driven by ionic fluxes and water entry (discussed in Erent et al⁸). VWF, like mucins, is stored at high concentration, and the condensation and aggregation of these proteins are facilitated by charge shielding by cationic species including hydrogen ion (H⁺) and Ca²⁺. The acidic lumen of the WPB is particularly important for VWF expulsion. Loss of H⁺ following fusion pore formation precedes postfusion changes in WPB morphology and rapid VWF expulsion, and both processes can be blocked simply by lowering the external pH close to that of the prefusion mature WPB.¹⁰ Thus, VWF expulsion from WPBs during histamine- or Ca²⁺-mediated exocytosis utilizes a beautifully simple mechanism that depends, in essence, on the chemistry of VWF and the intracellular processes that ensure its condensation and aggregation for storage at high concentration.

Is this mechanism likely to be of physiological relevance? Following injury, endothelial cells must function rapidly to minimize blood loss. The earliest event within these endothelial cells will be an increase in $[Ca^{2+}]_i$ produced either by cell damage, physicomechanical stimulation, or acute activation by physiological mediators generated locally at the injury site (eg, thrombin, histamine, fibrin, adenine nucleotides, and peptidoleukotrienes). Together, these mediators ensure rapid VWF expulsion to the endothelial cell surface to capture platelets and facilitate hemostasis.

Clearly, there is more than one way to unpack a WPB. Further studies will be needed to clarify the specific physiological conditions subserved by actomyosin-dependent and -independent VWF delivery to the endothelial cell surface.



Figure 1. Fast actomyosin-independent VWF expulsion from WPBs during Ca²⁺-mediated exocytosis. In the absence of flow, secreted VWF concatemers form irregularshaped patches on the cell surface and disperse slowly into solution. Importantly, the initial expulsion of VWF from WPBs and the subsequent dispersal from the cell surface constitute separate processes. (Ai) Montages of individual WPB exocytotic events taken from live-cell videos of histamine-stimulated human umbilical vein endothelial cells (HUVECs) expressing VWF-EGFP (top) or VWFpp-EGFP (bottom). Images were acquired at 10 frames per second. The first frame in which an increase in EGFP fluorescence due to fusion was detected is set to t = 0 seconds. Bars represent 2 μ m. (Aii) Histograms of the pooled times, from t = 0 seconds to expulsion, indicated by formation of irregular patches of cell surface VWF-EGFP (gray bars) or VWF-EGFP (black bars) from individual WPBs after stimulation with histamine or ionomycin. For VWF-EGFP, n = 543 fusion events (100 µM histamine, n = 183, 10 cells; 1 µM ionomycin, n = 310, 11 cells); for VWFpp-EGFP, n = 402 fusion events (100 µM histamine, n = 92, 7 cells; 1 µM ionomycin, n = 310, 13 cells). (Bi) Dualcolor imaging of a single HUVEC coexpressing VWFpp-EGFP and TagRFP-actin. Bar represents 10 µm. (Bii) Upper: Image montage of a single WPB undergoing exocytosis during ionomycin stimulation; EGFP fluorescence (top), RFP fluorescence (middle), merge image (bottom). Images were acquired at 30 frames per second, and selected frames (times indicated) are shown. Bar represents 2 µm. Lower: Mean fluorescence intensity (FI) within the color-coded regions of interest indicated on the first frame of the upper panel top row, plotted against time. WPB fusion is associated with a sharp increase in EGFP fluorescence due to EGFP-dequenching.⁸ Note that there was no evidence of RFP-actin accumulation prior to or during WPB exocytosis (n = 136 fusion events, 12 cells). (Ci-ii) Same as for panel Bi-ii, but in HUVECs coexpressing MyoIIB-GFP and VWFpp-mRFP. Note that there was no evidence of MyoIIB-EGFP accumulation prior to or during WPB exocytosis (n = 24 fusion events, 5 cells). Also note that RFP fluorescence is not pH sensitive, and exocytosis, therefore, is marked only by a fall in WPB associated RFP fluorescence. (D) Blebbistatin (Blebb) treatment (25 µM for 20 minutes; red bars) does not alter basal (-), histamine-evoked (100 µM; +), or ionomycin-evoked (1 µM; +) VWF secretion. Plots show data pooled from 3 independent experiments each carried out in triplicate (mean ± standard error of the mean). (E) Examples of individual WPB current spikes recorded by amperometry in control (black) and Blebb-pretreated (red) HUVECs. The kinetics of current spike foot signals and main spike rise times provide information about fusion pore formation and expansion. Mean (± standard error of the mean) pre-foot spike parameters, including foot signal duration (t_{foot} ; control: 13.72 \pm 3.31 ms, n = 216, 44 cells; Blebb: 9.85 \pm 1.09 ms, n = 256, 50 cells) and total foot signal charge (Q_{root}; control: 0.057 ± 0.013 pC; Blebb: 0.0636 ± 0.0147 pC), were no different (Student *t* test). Mean main spike parameters, including spike rise time (t_{rise}, control: 3.22 ± 0.17 ms, n = 317 spikes, 44 cells; Blebb: 3.26 ± 0.15 ms, n = 384 spikes, 50 cells), peak amplitude (I_{max}: control: 29.14 ± 1.31 pA; Blebb: 27.96 ± 1.11 pA), and spike decay time (t_{fall}; control: 15.08 ± 1.09 ms; Blebb: 13.64 ± 0.84 ms), were not different (Student *t* test). a.u., arbitrary unit; GFP, green fluorescent protein; RFP, red fluorescent protein.

lanina L. Conte

Cardiovascular and Cell Science Research Institute, St George's University, London, United Kingdom

Emma Cookson

The Francis Crick Institute Mill Hill Laboratory, London, United Kingdom

Nicola Hellen

The Francis Crick Institute Mill Hill Laboratory, London, United Kingdom

Ruben Bierings

The Francis Crick Institute Mill Hill Laboratory, London, United Kingdom

Gregory Mashanov

The Francis Crick Institute Mill Hill Laboratory, London, United Kingdom

Tom Carter

Cardiovascular and Cell Science Research Institute, St George's University, London, United Kingdom

Acknowledgments: The authors thank Dr Justin Molloy (Francis Crick Institute Mill Hill Laboratory, London, United Kingdom) for assistance with total internal reflection fluorescence microscopy and for critical reading of the manuscript, and Dr Matthew J. Hannah for critical comments on the manuscript. MyoIIB-GFP was kindly provided by Dr R. S. Adelstein (National Institutes of Health National Heart, Lung, and Blood Institute, Bethesda, MD). T.C. was funded by the United Kingdom Medical Research Council grant U117573808. R.B. was supported by

a European Hematology Association Research Fellowship. Contribution: I.L.C., E.C., N.H., R.B., G.M., and T.C. designed and performed the

research and analyzed the data; and I.L.C., N.H., R.B., and T.C. designed and performed the

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for E.C. is Department of Neuroscience, University of Wisconsin, Madison, WI.

The current affiliation for N.H. is National Heart and Lung Institute, Imperial College, London, United Kingdom.

The current affiliation for R.B. is Department of Plasma Proteins, Sanquin-AMC Landsteiner Laboratory, Amsterdam, The Netherlands.

Correspondence: T. Carter, Cardiovascular and Cell Science Research Institute, St George's University, Cranmer Terrace, London SW17 0RE, United Kingdom; e-mail: tcarter@sgul.ac.uk.

References

- Springer TA. von Willebrand factor, Jedi knight of the bloodstream. Blood. 2014; 124(9):1412-1425.
- Nightingale TD, White IJ, Doyle EL, et al. Actomyosin II contractility expels von Willebrand factor from Weibel-Palade bodies during exocytosis. J Cell Biol. 2011;194(4):613-629.
- Porat-Shliom N, Milberg O, Masedunskas A, Weigert R. Multiple roles for the actin cytoskeleton during regulated exocytosis. *Cell Mol Life Sci.* 2013;70(12): 2099-2121.
- Nightingale TD, Cutler DF, Cramer LP. Actin coats and rings promote regulated exocytosis. Trends Cell Biol. 2012;22(6):329-337.
- Marks MS, Heijnen HF, Raposo G. Lysosome-related organelles: unusual compartments become mainstream. Curr Opin Cell Biol. 2013;25(4):495-505.
- Carew MA, Paleolog EM, Pearson JD. The roles of protein kinase C and intracellular Ca2+ in the secretion of von Willebrand factor from human vascular endothelial cells. *Biochem J.* 1992;286(2):631-635.
- Nightingale TD, Pattni K, Hume AN, Seabra MC, Cutler DF. Rab27a and MyRIP regulate the amount and multimeric state of VWF released from endothelial cells. *Blood.* 2009;113(20):5010-5018.
- Erent M, Meli A, Moisoi N, et al. Rate, extent and concentration dependence of histamine-evoked Weibel-Palade body exocytosis determined from individual fusion events in human endothelial cells. J Physiol. 2007;583(1):195-212.
- Vischer UM, Barth H, Wollheim CB. Regulated von Willebrand factor secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells. *Arterioscler Thromb Vasc Biol.* 2000;20(3):883-891.
- Babich V, Knipe L, Hewlett L, et al. Differential effect of extracellular acidosis on the release and dispersal of soluble and membrane proteins secreted from the Weibel-Palade body. J Biol Chem. 2009;284(18):12459-12468.

DOI 10.1182/blood-2015-08-664961

© 2015 by The American Society of Hematology